A Phase 2 interventional study of LY3437943 and Placebo in Obesity and Overweight, sponsored by Eli Lilly and Company. Completed at 28 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-09-13.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing retatrutide in Obesity — 1 open to participants now, 6 under way, 5 of them phase 3. retatrutide · Obesity.
Among the 16 studies testing retatrutide in Obesity, this one is the 9th largest by enrollment, is the only one that started in 2021, is one of 3 in phase 2, and was the 1st registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →1 of the 16 studies testing retatrutide in Obesity is open now, in 1 country. Recruiting first, the newest first:
Hudson Biotech · Sites in China
Ages 18–75
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, retatrutide is the treatment under test here. Read study by study →
16 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 338 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 392 across the 16 interventional studies. Of the 10 that completed or were terminated, 2 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 16 have an industry lead sponsor. The 2 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
118 studies in Obesity by Eli Lilly and Company: 31 open now, 55 under way, 30 of them phase 3. Of 61 finished, 29 (48%) have results posted.
Among the 118 studies in Obesity by Eli Lilly and Company, this one is the 51st largest by enrollment of the 117 interventional ones that give a count, is one of 8 that started in 2021, is one of 22 in phase 2, and was the 11th registered.
Eli Lilly and Company’s Obesity studies by the year they started, since 2009.
4 of the studies testing retatrutide in Obesity that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06662383Phase 3Eli Lilly and CompanyA Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity | 2026-11 |
| NCT07232719Phase 3Eli Lilly and CompanyA Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight | 2027-06 |
| NCT07035093Phase 3Eli Lilly and CompanyA Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain | 2027-09 |
| NCT07467447Hudson BiotechEffect of Retatrutide Versus Placebo in Participants Who Have Obesity or Are Overweight | 2027-03-14 |
Add all 4 to your calendar (.ics) → With an account.
Among the 16 studies testing retatrutide in Obesity, from their registry updates:
Among Eli Lilly and Company’s 118 in Obesity:
This tab as a report to print or save as PDF → With an account.
This is a study of LY3437943 in participants who have obesity or are overweight. The main purpose is to learn more about how LY3437943 affects body weight loss. The study will last about 18 months and may include up to 18 visits.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo matched to LY3437943 administered as subcutaneous (SC) injection once-weekly (QW).
Drug: Placebo
Participants received 1 mg LY3437943 administered as SC injection QW.
Drug: LY3437943
Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW.
Drug: LY3437943
Participants received 4 mg LY3437943 administered as SC injection QW.
Drug: LY3437943
Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW.
Drug: LY3437943
Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW.
Drug: LY3437943
Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, 8 mg LY3437943 and then 12 mg LY3437943 administered as SC injection QW.
Drug: LY3437943
Administered SC
Administered SC
Mean Percent Change From Baseline in Body Weight
Least squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) for post-baseline measures: Variable = Treatment\*Time + Baseline BMI (\< 36kg/m2 vs. \>=36 kg/m2)\*Time + Sex (Female vs. Male)\*Time + Baseline\*Time.
Time frame: Baseline, Week 24
Mean Percent Change From Baseline in Body Weight
LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment\*Time + Baseline BMI (\< 36kg/m2 vs. \>=36 kg/m2)\*Time + Sex (Female vs. Male)\*Time + Baseline\*Time.
Time frame: Baseline, Week 48
Percentage of Participants Who Achieve ≥ 5% Body Weight Reduction
Percentage of participants who achieve ≥ 5% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum \[\<36 kilograms per square meter (kg/m2), ≥36 kg/m2\] and sex \[female, male\] as fixed effects, and baseline body weight as a covariate.
Time frame: Week 24
Percentage of Participants Who Achieve ≥ 5% Body Weight Reduction
Percentage of participants who achieve ≥ 5% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum \[\<36 kg/m2, ≥36 kg/m2\] and sex \[female, male\] as fixed effects, and baseline body weight as a covariate.
Time frame: Week 48
Percentage of Participants Who Achieve ≥ 10% Body Weight Reduction
Percentage of participants who achieve ≥ 10% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum \[\<36 kg/m2, ≥36 kg/m2\] and sex \[female, male\] as fixed effects, and baseline body weight as a covariate.
Time frame: Week 24
Percentage of Participants Who Achieve ≥ 10% Body Weight Reduction
Percentage of participants who achieve ≥ 10% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum \[\<36 kg/m2, ≥36 kg/m2\] and sex \[female, male\] as fixed effects, and baseline body weight as a covariate.
Time frame: Week 48
Percentage of Participants Who Achieve ≥ 15% Body Weight Reduction
Percentage of participants who achieve ≥ 15% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum \[\<36 kg/m2, ≥36 kg/m2\] and sex \[female, male\] as fixed effects, and baseline body weight as a covariate.
Time frame: Week 24
Percentage of Participants Who Achieve ≥ 15% Body Weight Reduction
Percentage of participants who achieve ≥ 15% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum \[\<36 kg/m2, ≥36 kg/m2\] and sex \[female, male\] as fixed effects, and baseline body weight as a covariate.
Time frame: Week 48
Mean Change From Baseline in Body Weight
LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment\*Time + Baseline BMI (\< 36kg/m2 vs. \>=36 kg/m2)\*Time + Sex (Female vs. Male)\*Time + Baseline\*Time.
Time frame: Baseline, Week 24
Mean Change From Baseline in Body Weight
LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment\*Time + Baseline BMI (\< 36kg/m2 vs. \>=36 kg/m2)\*Time + Sex (Female vs. Male)\*Time + Baseline\*Time.
Time frame: Baseline, Week 48
Mean Change From Baseline in BMI
LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment\*Time + Baseline BMI (\< 36kg/m2 vs. \>=36 kg/m2)\*Time + Sex (Female vs. Male)\*Time + Baseline\*Time.
Time frame: Baseline, Week 24
Mean Change From Baseline in BMI
LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment\*Time + Baseline BMI (\< 36kg/m2 vs. \>=36 kg/m2)\*Time + Sex (Female vs. Male)\*Time + Baseline\*Time.
Time frame: Baseline, Week 48
Mean Change From Baseline in Waist Circumference
LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment\*Time + Baseline BMI (\< 36kg/m2 vs. \>=36 kg/m2)\*Time + Sex (Female vs. Male)\*Time + Baseline\*Time.
Time frame: Baseline, Week 24
Mean Change From Baseline in Waist Circumference
LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment\*Time + Baseline BMI (\< 36kg/m2 vs. \>=36 kg/m2)\*Time + Sex (Female vs. Male)\*Time + Baseline\*Time.
Time frame: Baseline, Week 48
| Milestone | Placebo | 1 mg LY3437943 | 4 mg LY3437943 (2 mg) | 4 mg LY3437943 | 8 mg LY3437943 (2 mg) | 8 mg LY3437943 (4 mg) | 12 mg LY3437943 (2 mg) |
|---|---|---|---|---|---|---|---|
| Started | 70 | 69 | 33 | 34 | 35 | 35 | 62 |
| Received at least one dose of study drug | 70 | 69 | 33 | 33 | 35 | 35 | 62 |
| Completed | 50 | 60 | 26 | 26 | 30 | 29 | 54 |
| Not completed | 20 | 9 | 7 | 8 | 5 | 6 | 8 |
| Withdrew: Adverse event | 0 | 1 | 1 | 0 | 1 | 1 | 2 |
| Withdrew: Death | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 5 | 7 | 5 | 1 | 2 | 4 | 4 |
| Withdrew: Withdrawal by subject | 13 | 1 | 1 | 4 | 2 | 1 | 2 |
| Withdrew: Randomized but never treated | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Inadvertent enrollment | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Site closure | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
Least squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) for post-baseline measures: Variable = Treatment\*Time + Baseline BMI (\< 36kg/m2 vs. \>=36 kg/m2)\*Time + Sex (Female vs. Male)\*Time + Baseline\*Time.
| percent change | Placebo | 1 mg LY3437943 | 4 mg LY3437943 (2 mg) | 4 mg LY3437943 | 8 mg LY3437943 (2 mg) | 8 mg LY3437943 (4 mg) | 12 mg LY3437943 (2 mg) |
|---|---|---|---|---|---|---|---|
| Mean Percent Change From Baseline in Body Weight | -1.55 ± 0.54 | -7.18 ± 0.67 | -12.00 ± 0.71 | -13.80 ± 0.97 | -16.64 ± 0.74 | -18.26 ± 0.95 | -17.39 ± 0.69 |
LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment\*Time + Baseline BMI (\< 36kg/m2 vs. \>=36 kg/m2)\*Time + Sex (Female vs. Male)\*Time + Baseline\*Time.
| percent change | Placebo | 1 mg LY3437943 | 4 mg LY3437943 (2 mg) | 4 mg LY3437943 | 8 mg LY3437943 (2 mg) | 8 mg LY3437943 (4 mg) | 12 mg LY3437943 (2 mg) |
|---|---|---|---|---|---|---|---|
| Mean Percent Change From Baseline in Body Weight | -2.11 ± 0.73 | -8.67 ± 0.95 | -16.32 ± 1.58 | -17.83 ± 1.53 | -21.72 ± 1.41 | -23.88 ± 1.51 | -24.22 ± 1.24 |
Percentage of participants who achieve ≥ 5% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum \[\<36 kilograms per square meter (kg/m2), ≥36 kg/m2\] and sex \[female, male\] as fixed effects, and baseline body weight as a covariate.
| percentage of participants | Placebo | 1 mg LY3437943 | 4 mg LY3437943 (2 mg) | 4 mg LY3437943 | 8 mg LY3437943 (2 mg) | 8 mg LY3437943 (4 mg) | 12 mg LY3437943 (2 mg) |
|---|---|---|---|---|---|---|---|
| Percentage of Participants Who Achieve ≥ 5% Body Weight Reduction | 26 | 59 | 87 | 94 | 100 | 100 | 97 |
Percentage of participants who achieve ≥ 5% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum \[\<36 kg/m2, ≥36 kg/m2\] and sex \[female, male\] as fixed effects, and baseline body weight as a covariate.
| percentage of participants | Placebo | 1 mg LY3437943 | 4 mg LY3437943 (2 mg) | 4 mg LY3437943 | 8 mg LY3437943 (2 mg) | 8 mg LY3437943 (4 mg) | 12 mg LY3437943 (2 mg) |
|---|---|---|---|---|---|---|---|
| Percentage of Participants Who Achieve ≥ 5% Body Weight Reduction | 27 | 64 | 87 | 97 | 100 | 100 | 100 |
Percentage of participants who achieve ≥ 10% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum \[\<36 kg/m2, ≥36 kg/m2\] and sex \[female, male\] as fixed effects, and baseline body weight as a covariate.
| percentage of participants | Placebo | 1 mg LY3437943 | 4 mg LY3437943 (2 mg) | 4 mg LY3437943 | 8 mg LY3437943 (2 mg) | 8 mg LY3437943 (4 mg) | 12 mg LY3437943 (2 mg) |
|---|---|---|---|---|---|---|---|
| Percentage of Participants Who Achieve ≥ 10% Body Weight Reduction | 3 | 25 | 59 | 72 | 83 | 94 | 90 |
Percentage of participants who achieve ≥ 10% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum \[\<36 kg/m2, ≥36 kg/m2\] and sex \[female, male\] as fixed effects, and baseline body weight as a covariate.
| percentage of participants | Placebo | 1 mg LY3437943 | 4 mg LY3437943 (2 mg) | 4 mg LY3437943 | 8 mg LY3437943 (2 mg) | 8 mg LY3437943 (4 mg) | 12 mg LY3437943 (2 mg) |
|---|---|---|---|---|---|---|---|
| Percentage of Participants Who Achieve ≥ 10% Body Weight Reduction | 9 | 27 | 73 | 76 | 90 | 91 | 93 |
Percentage of participants who achieve ≥ 15% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum \[\<36 kg/m2, ≥36 kg/m2\] and sex \[female, male\] as fixed effects, and baseline body weight as a covariate.
| percentage of participants | Placebo | 1 mg LY3437943 | 4 mg LY3437943 (2 mg) | 4 mg LY3437943 | 8 mg LY3437943 (2 mg) | 8 mg LY3437943 (4 mg) | 12 mg LY3437943 (2 mg) |
|---|---|---|---|---|---|---|---|
| Percentage of Participants Who Achieve ≥ 15% Body Weight Reduction | 1 | 10 | 29 | 44 | 51 | 68 | 70 |
Percentage of participants who achieve ≥ 15% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum \[\<36 kg/m2, ≥36 kg/m2\] and sex \[female, male\] as fixed effects, and baseline body weight as a covariate.
| percentage of participants | Placebo | 1 mg LY3437943 | 4 mg LY3437943 (2 mg) | 4 mg LY3437943 | 8 mg LY3437943 (2 mg) | 8 mg LY3437943 (4 mg) | 12 mg LY3437943 (2 mg) |
|---|---|---|---|---|---|---|---|
| Percentage of Participants Who Achieve ≥ 15% Body Weight Reduction | 2 | 16 | 55 | 64 | 73 | 77 | 83 |
LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment\*Time + Baseline BMI (\< 36kg/m2 vs. \>=36 kg/m2)\*Time + Sex (Female vs. Male)\*Time + Baseline\*Time.
| kilograms (kg) | Placebo | 1 mg LY3437943 | 4 mg LY3437943 (2 mg) | 4 mg LY3437943 | 8 mg LY3437943 (2 mg) | 8 mg LY3437943 (4 mg) | 12 mg LY3437943 (2 mg) |
|---|---|---|---|---|---|---|---|
| Mean Change From Baseline in Body Weight | -1.27 ± 0.63 | -7.72 ± 0.73 | -12.59 ± 0.81 | -14.79 ± 1.09 | -17.70 ± 0.79 | -19.75 ± 1.08 | -18.53 ± 0.71 |
LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment\*Time + Baseline BMI (\< 36kg/m2 vs. \>=36 kg/m2)\*Time + Sex (Female vs. Male)\*Time + Baseline\*Time.
| kg | Placebo | 1 mg LY3437943 | 4 mg LY3437943 (2 mg) | 4 mg LY3437943 | 8 mg LY3437943 (2 mg) | 8 mg LY3437943 (4 mg) | 12 mg LY3437943 (2 mg) |
|---|---|---|---|---|---|---|---|
| Mean Change From Baseline in Body Weight | -1.84 ± 0.83 | -9.37 ± 1.06 | -17.32 ± 1.78 | -19.13 ± 1.80 | -23.52 ± 1.61 | -25.88 ± 1.68 | -26.17 ± 1.33 |
LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment\*Time + Baseline BMI (\< 36kg/m2 vs. \>=36 kg/m2)\*Time + Sex (Female vs. Male)\*Time + Baseline\*Time.
| kg/m^2 | Placebo | 1 mg LY3437943 | 4 mg LY3437943 (2 mg) | 4 mg LY3437943 | 8 mg LY3437943 (2 mg) | 8 mg LY3437943 (4 mg) | 12 mg LY3437943 (2 mg) |
|---|---|---|---|---|---|---|---|
| Mean Change From Baseline in BMI | -0.49 ± 0.21 | -2.64 ± 0.26 | -4.47 ± 0.28 | -5.13 ± 0.36 | -6.15 ± 0.27 | -6.84 ± 0.36 | -6.44 ± 0.25 |
LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment\*Time + Baseline BMI (\< 36kg/m2 vs. \>=36 kg/m2)\*Time + Sex (Female vs. Male)\*Time + Baseline\*Time.
| kg/m^2 | Placebo | 1 mg LY3437943 | 4 mg LY3437943 (2 mg) | 4 mg LY3437943 | 8 mg LY3437943 (2 mg) | 8 mg LY3437943 (4 mg) | 12 mg LY3437943 (2 mg) |
|---|---|---|---|---|---|---|---|
| Mean Change From Baseline in BMI | -0.72 ± 0.29 | -3.22 ± 0.37 | -6.14 ± 0.65 | -6.67 ± 0.59 | -8.12 ± 0.55 | -9.02 ± 0.57 | -9.14 ± 0.46 |
LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment\*Time + Baseline BMI (\< 36kg/m2 vs. \>=36 kg/m2)\*Time + Sex (Female vs. Male)\*Time + Baseline\*Time.
| centimeters (cm) | Placebo | 1 mg LY3437943 | 4 mg LY3437943 (2 mg) | 4 mg LY3437943 | 8 mg LY3437943 (2 mg) | 8 mg LY3437943 (4 mg) | 12 mg LY3437943 (2 mg) |
|---|---|---|---|---|---|---|---|
| Mean Change From Baseline in Waist Circumference | -2.60 ± 0.80 | -5.43 ± 0.94 | -10.33 ± 1.05 | -12.55 ± 1.00 | -13.74 ± 1.04 | -14.99 ± 0.98 | -14.33 ± 0.86 |
LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment\*Time + Baseline BMI (\< 36kg/m2 vs. \>=36 kg/m2)\*Time + Sex (Female vs. Male)\*Time + Baseline\*Time.
| cm | Placebo | 1 mg LY3437943 | 4 mg LY3437943 (2 mg) | 4 mg LY3437943 | 8 mg LY3437943 (2 mg) | 8 mg LY3437943 (4 mg) | 12 mg LY3437943 (2 mg) |
|---|---|---|---|---|---|---|---|
| Mean Change From Baseline in Waist Circumference | -2.64 ± 0.99 | -6.49 ± 1.12 | -14.58 ± 1.56 | -14.87 ± 1.73 | -18.53 ± 1.46 | -18.50 ± 1.52 | -19.60 ± 1.29 |
Collected over Baseline Through End of Safety Follow-up (Up to 52 Weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/70 (0%) | 3/70 (4.3%) | 40/70 (57.1%) |
| 1 mg LY3437943 | 0/69 (0%) | 3/69 (4.3%) | 46/69 (66.7%) |
| 4 mg LY3437943 (2 mg) | 0/33 (0%) | 0/33 (0%) | 22/33 (66.7%) |
| 4 mg LY3437943 | 1/33 (3%) | 2/33 (6.1%) | 24/33 (72.7%) |
| 8 mg LY3437943 (2 mg) | 0/35 (0%) | 1/35 (2.9%) | 26/35 (74.3%) |
| 8 mg LY3437943 (4 mg) | 0/35 (0%) | 2/35 (5.7%) | 31/35 (88.6%) |
| 12 mg LY3437943 (2 mg) | 0/62 (0%) | 2/62 (3.2%) | 52/62 (83.9%) |
| Event | Placebo | 1 mg LY3437943 | 4 mg LY3437943 (2 mg) | 4 mg LY3437943 | 8 mg LY3437943 (2 mg) | 8 mg LY3437943 (4 mg) | 12 mg LY3437943 (2 mg) |
|---|---|---|---|---|---|---|---|
| DrowningGeneral disorders | 0/70 | 0/69 | 0/33 | 1/33 | 0/35 | 0/35 | 0/62 |
| Clear cell renal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/70 | 0/69 | 0/33 | 1/33 | 0/35 | 0/35 | 0/62 |
| Cerebrovascular accidentNervous system disorders | 0/70 | 2/69 | 0/33 | 0/33 | 0/35 | 0/35 | 0/62 |
| Cardiac failureCardiac disorders | 0/70 | 0/69 | 0/33 | 0/33 | 1/35 | 0/35 | 0/62 |
| VomitingGastrointestinal disorders | 0/70 | 0/69 | 0/33 | 0/33 | 0/35 | 1/35 | 0/62 |
| Cholecystitis acuteHepatobiliary disorders | 0/70 | 0/69 | 0/33 | 0/33 | 0/35 | 1/35 | 0/62 |
| Covid-19Infections and infestations | 0/70 | 0/69 | 0/33 | 0/33 | 0/35 | 1/35 | 0/62 |
| Acute kidney injuryRenal and urinary disorders | 0/70 | 0/69 | 0/33 | 0/33 | 0/35 | 1/35 | 0/62 |
| Pancreatitis acuteGastrointestinal disorders | 0/70 | 0/69 | 0/33 | 0/33 | 0/35 | 0/35 | 1/62 |
| Electrocardiogram qt prolongedInvestigations | 0/70 | 0/69 | 0/33 | 0/33 | 0/35 | 0/35 | 1/62 |
| Event | Placebo | 1 mg LY3437943 | 4 mg LY3437943 (2 mg) | 4 mg LY3437943 | 8 mg LY3437943 (2 mg) | 8 mg LY3437943 (4 mg) | 12 mg LY3437943 (2 mg) |
|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 8/70 | 10/69 | 6/33 | 12/33 | 6/35 | 21/35 | 28/62 |
| Covid-19Infections and infestations | 14/70 | 13/69 | 4/33 | 6/33 | 6/35 | 11/35 | 15/62 |
| Decreased appetiteMetabolism and nutrition disorders | 6/70 | 9/69 | 6/33 | 8/33 | 4/35 | 11/35 | 18/62 |
| VomitingGastrointestinal disorders | 1/70 | 2/69 | 4/33 | 4/33 | 2/35 | 9/35 | 12/62 |
| DiarrhoeaGastrointestinal disorders | 8/70 | 6/69 | 4/33 | 4/33 | 7/35 | 7/35 | 9/62 |
| ConstipationGastrointestinal disorders | 2/70 | 5/69 | 5/33 | 2/33 | 4/35 | 4/35 | 10/62 |
| FatigueGeneral disorders | 3/70 | 3/69 | 4/33 | 2/33 | 1/35 | 3/35 | 6/62 |
| HeadacheNervous system disorders | 0/70 | 2/69 | 1/33 | 0/33 | 0/35 | 4/35 | 4/62 |
| Early satietyGeneral disorders | 4/70 | 3/69 | 1/33 | 1/33 | 0/35 | 2/35 | 6/62 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 1/70 | 1/69 | 2/33 | 3/33 | 3/35 | 0/35 | 4/62 |
All randomized participants.
| Age, Continuous(years) | Placebo | 1 mg LY3437943 | 4 mg LY3437943 (2 mg) | 4 mg LY3437943 | 8 mg LY3437943 (2 mg) | 8 mg LY343794 (4 mg) | 12 mg LY3437943 (2 mg) | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 48.00 ± 12.54 | 50.60 ± 13.30 | 50.80 ± 11.88 | 46.80 ± 14.10 | 46.10 ± 13.52 | 48.70 ± 11.14 | 45.80 ± 12.18 | 48.20 ± 12.73 |
| Sex: Female, Male(Participants) | Placebo | 1 mg LY3437943 | 4 mg LY3437943 (2 mg) | 4 mg LY3437943 | 8 mg LY3437943 (2 mg) | 8 mg LY343794 (4 mg) | 12 mg LY3437943 (2 mg) | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 34 | 33 | 16 | 16 | 17 | 17 | 30 | 163 |
| Male | 36 | 36 | 17 | 18 | 18 | 18 | 32 | 175 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | 1 mg LY3437943 | 4 mg LY3437943 (2 mg) | 4 mg LY3437943 | 8 mg LY3437943 (2 mg) | 8 mg LY343794 (4 mg) | 12 mg LY3437943 (2 mg) | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 22 | 23 | 9 | 14 | 15 | 12 | 22 | 117 |
| Not Hispanic or Latino | 47 | 46 | 24 | 20 | 20 | 23 | 40 | 220 |
| Unknown or Not Reported | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Placebo | 1 mg LY3437943 | 4 mg LY3437943 (2 mg) | 4 mg LY3437943 | 8 mg LY3437943 (2 mg) | 8 mg LY343794 (4 mg) | 12 mg LY3437943 (2 mg) | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 2 |
| Asian | 2 | 0 | 0 | 0 | 1 | 0 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Black or African American | 8 | 6 | 4 | 2 | 4 | 1 | 2 | 27 |
| White | 59 | 61 | 29 | 30 | 30 | 33 | 56 | 298 |
| More than one race | 1 | 0 | 0 | 1 | 0 | 1 | 2 | 5 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Region of Enrollment(participants) | Placebo | 1 mg LY3437943 | 4 mg LY3437943 (2 mg) | 4 mg LY3437943 | 8 mg LY3437943 (2 mg) | 8 mg LY343794 (4 mg) | 12 mg LY3437943 (2 mg) | Total |
|---|---|---|---|---|---|---|---|---|
| United States | 70 | 69 | 33 | 34 | 35 | 35 | 62 | 338 |
| Baseline Body Weight(kilograms (kg)) | Placebo | 1 mg LY3437943 | 4 mg LY3437943 (2 mg) | 4 mg LY3437943 | 8 mg LY3437943 (2 mg) | 8 mg LY343794 (4 mg) | 12 mg LY3437943 (2 mg) | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 109.21 ± 20.88 | 106.36 ± 19.84 | 108.04 ± 26.31 | 107.01 ± 21.29 | 106.50 ± 21.55 | 108.63 ± 20.88 | 107.97 ± 21.69 | 107.73 ± 21.35 |
| Baseline Body Mass Index (BMI)(kilograms per meter squared (kg/m^2)) | Placebo | 1 mg LY3437943 | 4 mg LY3437943 (2 mg) | 4 mg LY3437943 | 8 mg LY3437943 (2 mg) | 8 mg LY343794 (4 mg) | 12 mg LY3437943 (2 mg) | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 37.31 ± 5.90 | 37.49 ± 5.85 | 37.27 ± 5.87 | 37.39 ± 4.66 | 37.37 ± 6.04 | 36.96 ± 5.49 | 37.42 ± 5.98 | 37.34 ± 5.71 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from May 2021 to primary completion in May 2022, 11 months.
Results were first posted in Sep 2023, 1 year 3 months after primary completion. A results delay was requested in May 2023.
Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 11 months is close to that.
Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Retatrutide